#Japan #Tokyo #Eisai #Leqembi #Alzheimer

Positive Impact of LEQEMBI® in Alzheimer's Treatment

The recent LEADER study, which focuses on the real-world impact of LEQEMBI® (lecanemab), has provided new insights into its effectiveness for patients with early Alzheimer's disease (AD). Presented at the Alzheimer's Association International Conference 2026 (AAIC 2026) in London, these findings indicate significant stability and improvement among participants who underwent treatment with the drug over an average period of 17 months.

According to the data from the study conducted by Eisai Co., Ltd. and Biogen Inc., around 83% of the early-stage Alzheimer's patients enrolled remained stable or showed improvement while on LEQEMBI therapy. Specifically, 75.9% of participants maintained their condition, while an encouraging 6.6% experienced a noticeable improvement in their cognitive functions.

Study Overview and Participant Demographics

The LEADER study is a multicenter investigation that utilized a retrospective approach to examine various aspects of LEQEMBI utilization in real-world settings. With 432 patients in total, the demographic breakdown shows a mean age of 74 years, where a majority, specifically 55.8%, were female. Prior to the study, 63.9% of participants were identified with mild cognitive impairment due to AD, while 36.1% were diagnosed with mild AD dementia.

The treatment regimen involved an average of 26 doses of LEQEMBI administered over approximately 520 days, allowing researchers to closely monitor changes in participants’ disease states.

Findings Across Different Demographics

One of the remarkable aspects of these findings is the consistency across various demographics, including sex, race, ethnicity, and genetic predisposition as represented by the APOE genotype. The data revealed that both APOE ε4 carriers and non-carriers had similar rates of stability and improvement, highlighting the universal benefits of continuous treatment with LEQEMBI in managing early AD.

Nearly 87% of patients opted to continue their LEQEMBI treatment, indicating high patient retention and satisfaction levels regarding the therapeutic approach.

Maintenance Treatment Insights

Among the participants, a subgroup transitioned to maintenance therapies, with 155 individuals moving to intravenous maintenance therapy occurring every four weeks. Remarkably, nearly 81% of these participants demonstrated either stability or improvement in their condition. This suggests that switching to a maintenance dosage schedule maintains the drug’s efficacy and may enhance the quality of life for patients in this vulnerable population.

Safety Profile in the Real World

The safety profile observed in the real-world setting largely aligned with findings from clinical trials and the U.S. FDA-approved labeling. Approximately 12.3% of the participants experienced ARIA (amyloid-related imaging abnormalities), yet the majority were categorized as mild and asymptomatic. There were no reports of severe complications during the maintenance phase of treatment. Such findings reassure healthcare professionals regarding the safety of LEQEMBI when considering long-term treatment plans for patients.

Conclusion

In summary, the LEADER study reflects positively on the continuous use of LEQEMBI for early Alzheimer's patients. The ability of the drug to stabilize and even improve cognitive function in over 75% of treated individuals highlights its potential as a cornerstone in all-encompassing Alzheimer's management strategies. Additionally, the high retention rate of patients opting to remain on treatment underscores the need for continued research and the relevance of such therapies in enhancing patient care.

With Alzheimer’s disease being a progressive and debilitating condition, these findings are critical for both caregivers and healthcare providers as they navigate treatment options for individuals facing the challenges of early AD.